Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Halloran

Showing results (41-50 of 71) with videos related to

Pageof 8
Sort By:
Biometrics|April 25, 2001
Semiparametric methods for multiple exposure mismeasurement and a bivariate outcome in HIV vaccine trialsG T Golm, M E Halloran, I M Longini
Boletin Medico Del Hospital Infantil De Mexico|July 1, 1990
[Direct and indirect effects of vaccines: an annotation on the estimation of the vaccine efficacy from outbreaks caused by acute infection agents such as measles]I M Longini, M J Haber, M E Halloran
International Journal of Epidemiology|October 1, 1995
Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control studyC P Noronha, C J Struchiner, M E Halloran
Health Matrix|December 6, 1986
Nursing and medicine: changing roles and relationshipsD Silber, V A Cargill, E Halloran, et al.
American Journal of Epidemiology|November 15, 1996
Predictors of Chlamydia trachomatis infection among female adolescents: a longitudinal analysisD J Mosure, S Berman, D Kleinbaum, et al.
Statistics in Medicine|February 1, 1993
Measuring vaccine efficacy from epidemics of acute infectious agentsI M Longini, M E Halloran, M Haber, et al.
American Journal of Epidemiology|May 15, 1995
The effect of disease prior to an outbreak on estimates of vaccine efficacy following the outbreakM Haber, W A Orenstein, M E Halloran, et al.
Lancet (London, England)|November 11, 1989
Neutrophil elastases and haemolytic uraemic syndromeD Milford, C M Taylor, F Rafaat, et al.
Statistics in Medicine|June 10, 1998
Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populationsI M Longini, K Sagatelian, W N Rida, et al.
Statistics in Medicine|February 17, 1999
A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccinesI M Longini, M G Hudgens, M E Halloran, et al.
Pageof 8

Showing results (41-50 of 71) with videos related to

Sort By:
Pageof 8
Biometrics|April 25, 2001
Semiparametric methods for multiple exposure mismeasurement and a bivariate outcome in HIV vaccine trialsG T Golm, M E Halloran, I M Longini
Boletin Medico Del Hospital Infantil De Mexico|July 1, 1990
[Direct and indirect effects of vaccines: an annotation on the estimation of the vaccine efficacy from outbreaks caused by acute infection agents such as measles]I M Longini, M J Haber, M E Halloran
International Journal of Epidemiology|October 1, 1995
Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control studyC P Noronha, C J Struchiner, M E Halloran
Health Matrix|December 6, 1986
Nursing and medicine: changing roles and relationshipsD Silber, V A Cargill, E Halloran, et al.
American Journal of Epidemiology|November 15, 1996
Predictors of Chlamydia trachomatis infection among female adolescents: a longitudinal analysisD J Mosure, S Berman, D Kleinbaum, et al.
Statistics in Medicine|February 1, 1993
Measuring vaccine efficacy from epidemics of acute infectious agentsI M Longini, M E Halloran, M Haber, et al.
American Journal of Epidemiology|May 15, 1995
The effect of disease prior to an outbreak on estimates of vaccine efficacy following the outbreakM Haber, W A Orenstein, M E Halloran, et al.
Lancet (London, England)|November 11, 1989
Neutrophil elastases and haemolytic uraemic syndromeD Milford, C M Taylor, F Rafaat, et al.
Statistics in Medicine|June 10, 1998
Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populationsI M Longini, K Sagatelian, W N Rida, et al.
Statistics in Medicine|February 17, 1999
A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccinesI M Longini, M G Hudgens, M E Halloran, et al.
Pageof 8